These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 3124975

  • 1. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 3. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT.
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [Abstract] [Full Text] [Related]

  • 4. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
    Fitzgerald DJ, Wright F, FitzGerald GA.
    Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
    [Abstract] [Full Text] [Related]

  • 5. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries.
    Golino P, Buja LM, Ashton JH, Kulkarni P, Taylor A, Willerson JT.
    Circulation; 1988 Sep; 78(3):701-11. PubMed ID: 3409505
    [Abstract] [Full Text] [Related]

  • 6. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
    Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM.
    Circ Res; 1992 Jan; 70(1):39-48. PubMed ID: 1727687
    [Abstract] [Full Text] [Related]

  • 7. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ, Smith JM, Storer BL, Granett JR, Bugelski PJ.
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [Abstract] [Full Text] [Related]

  • 8. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 9. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 10. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 11. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses.
    Ashton JH, Ogletree ML, Michel IM, Golino P, McNatt JM, Taylor AL, Raheja S, Schmitz J, Buja LM, Campbell WB.
    Circulation; 1987 Oct; 76(4):952-9. PubMed ID: 3652429
    [Abstract] [Full Text] [Related]

  • 12. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ, Connolly TM, York SJ, Bush LR.
    Thromb Haemost; 1990 Dec 28; 64(4):526-34. PubMed ID: 2128137
    [Abstract] [Full Text] [Related]

  • 13. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar 28; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K, Karasawa A, Kubo K.
    Arzneimittelforschung; 1991 Dec 28; 41(12):1251-5. PubMed ID: 1815525
    [Abstract] [Full Text] [Related]

  • 15. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
    Fitzgerald DJ, Fitzgerald GA.
    Proc Natl Acad Sci U S A; 1989 Oct 28; 86(19):7585-9. PubMed ID: 2508092
    [Abstract] [Full Text] [Related]

  • 16. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D.
    J Am Coll Cardiol; 1989 May 28; 13(6):1409-14. PubMed ID: 2495318
    [Abstract] [Full Text] [Related]

  • 17. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR.
    Thromb Res; 1988 Jul 01; 51(1):63-74. PubMed ID: 3137691
    [Abstract] [Full Text] [Related]

  • 18. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
    Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D.
    Circulation; 1988 Mar 01; 77(3):670-7. PubMed ID: 3124974
    [Abstract] [Full Text] [Related]

  • 19. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr 01; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 20. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ, Follenfant MJ, Ford AJ.
    Cardiovasc Res; 1991 Mar 01; 25(3):184-91. PubMed ID: 1903080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.